The UK and US have reached a significant commercial pact that will guarantee zero import taxes on British drug products going into the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to raise spending on drugs through the National Health Service (NHS). This commitment secures that duties on these key goods will be held at nothing for a period of the next three years.
This agreement follows recent warnings to significantly raise duties on patented drug products, with increases discussed reaching double the cost.
"This agreement between the United Kingdom strengthens the international landscape for new treatments and introduces long-overdue fairness to U.S.–U.K. pharmaceutical trade," a statement noted.
Economic Significance
Pharmaceuticals constitute one of the UK's most significant exports to the United States, which is by far the primary market for large companies like GSK and AstraZeneca.
Trade data reveal that in the 12 months prior to last September, the UK exported drugs totaling over eleven billion pounds to the US. This value represented a significant portion of total UK exports in that timeframe.
"This agreement safeguards jobs, increases investment and paves the way for the UK to emerge as a worldwide center for medical research," a government official commented.
Key NHS Changes
The agreement involves several notable changes from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise total health service expenditure on medicines from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The percentage manufacturers must refund to the NHS to control costs will be capped at fifteen percent. Previously, repayments exceeded 20%.
Industry Background
This agreement follows a ongoing row between the drug companies and the British authorities over spending levels and approval rates.
These tensions were intensified by assertions that US patients were charged several times more for the same drugs than consumers in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been paused or cancelled, while major expansions have been pledged toward projects in the United States.
The Science Minister stated that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a percentage of its resources over the last ten years.
